Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research report sent to investors on Monday, Marketbeat reports. The firm issued an overweight rating and a $26.00 price target on the stock.

Several other equities analysts also recently weighed in on BBNX. Baird R W upgraded Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. LADENBURG THALM/SH SH started coverage on Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price objective on the stock. Leerink Partners assumed coverage on Beta Bionics in a research note on Monday. They set an “outperform” rating and a $28.00 price objective for the company. Finally, Robert W. Baird began coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.83.

Beta Bionics Trading Up 0.1 %

Shares of Beta Bionics stock opened at $20.60 on Monday. Beta Bionics has a 1-year low of $20.00 and a 1-year high of $24.50.

Insider Buying and Selling

In related news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of Beta Bionics stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the acquisition, the insider now owns 3,901,599 shares in the company, valued at approximately $66,327,183. The trade was a 34.46 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mike Mensinger acquired 33,350 shares of the company’s stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, with a total value of $566,950.00. Following the acquisition, the insider now directly owns 59,019 shares in the company, valued at approximately $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.